Prevalence and predictors of peripheral neuropathy after breast cancer treatment.
Peripheral neuropathy
breast cancer
cancer survivors
chemotherapy
taxane
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
revised:
26
07
2021
received:
05
06
2021
accepted:
29
07
2021
pubmed:
15
8
2021
medline:
3
3
2022
entrez:
14
8
2021
Statut:
ppublish
Résumé
Many of the 3.8 million breast cancer survivors in the United States experience long-term side effects of cancer therapy including peripheral neuropathy (PN). We assessed the prevalence and predictors of PN among women with breast cancer followed in the Women's Health Initiative's Life and Longevity After Cancer survivorship cohort. The study population included 2420 women with local (79%) or regional (21%) stage disease. Presence of PN was based on the reports of "nerve problems and/or tingling sensations" after treatment and PN severity was assessed using the Functional Assessment of Cancer Therapy-Gynecologic Oncology Group/Neurotoxicity instrument. Logistic regression analysis was used to evaluate the socio-demographic and clinical factors associated with PN prevalence and severity. Initial breast cancer treatment included surgery-only (21%), surgery and radiation (53%), or surgery and chemotherapy (±radiation) (26%). Overall, 17% of women reported PN occurring within days (30%), months (46%), or years (24%) after treatment and 74% reported ongoing symptoms at a median of 6.5 years since diagnosis. PN was reported by a larger proportion of chemotherapy recipients (33%) compared to those who had surgery alone (12%) or surgery+radiation (11%) (p < 0.0001). PN was reported more commonly by women treated with paclitaxel (52%) and docetaxel (39%), versus other chemotherapy (17%) (p < 0.0001). In multivariable analyses, treatment type (chemotherapy vs. none; OR, 95% CI: 3.31, 2.4-4.6), chemotherapy type (taxane vs. no-taxane; 4.74, 3.1-7.3), and taxane type (paclitaxel vs. docetaxel; 1.59, 1.0-2.5) were associated with higher odds of PN. PN is an important long-term consequence of taxane-based chemotherapy in breast cancer survivors.
Sections du résumé
BACKGROUND
Many of the 3.8 million breast cancer survivors in the United States experience long-term side effects of cancer therapy including peripheral neuropathy (PN). We assessed the prevalence and predictors of PN among women with breast cancer followed in the Women's Health Initiative's Life and Longevity After Cancer survivorship cohort.
METHODS
The study population included 2420 women with local (79%) or regional (21%) stage disease. Presence of PN was based on the reports of "nerve problems and/or tingling sensations" after treatment and PN severity was assessed using the Functional Assessment of Cancer Therapy-Gynecologic Oncology Group/Neurotoxicity instrument. Logistic regression analysis was used to evaluate the socio-demographic and clinical factors associated with PN prevalence and severity.
RESULTS
Initial breast cancer treatment included surgery-only (21%), surgery and radiation (53%), or surgery and chemotherapy (±radiation) (26%). Overall, 17% of women reported PN occurring within days (30%), months (46%), or years (24%) after treatment and 74% reported ongoing symptoms at a median of 6.5 years since diagnosis. PN was reported by a larger proportion of chemotherapy recipients (33%) compared to those who had surgery alone (12%) or surgery+radiation (11%) (p < 0.0001). PN was reported more commonly by women treated with paclitaxel (52%) and docetaxel (39%), versus other chemotherapy (17%) (p < 0.0001). In multivariable analyses, treatment type (chemotherapy vs. none; OR, 95% CI: 3.31, 2.4-4.6), chemotherapy type (taxane vs. no-taxane; 4.74, 3.1-7.3), and taxane type (paclitaxel vs. docetaxel; 1.59, 1.0-2.5) were associated with higher odds of PN.
CONCLUSION
PN is an important long-term consequence of taxane-based chemotherapy in breast cancer survivors.
Identifiants
pubmed: 34390205
doi: 10.1002/cam4.4202
pmc: PMC8495292
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
6666-6676Subventions
Organisme : NHLBI NIH HHS
ID : HHSN268201600002C
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA173642
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600004C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600001C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600003C
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA173642
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600018C
Pays : United States
Informations de copyright
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
J Natl Cancer Inst. 2018 Feb 1;110(2):
pubmed: 28954296
Neurology. 1999 Nov 10;53(8):1660-4
pubmed: 10563609
J Natl Cancer Inst. 2016 Oct 28;109(2):
pubmed: 27794123
Cancer Med. 2021 Oct;10(19):6666-6676
pubmed: 34390205
J Oncol Pract. 2013 Sep;9(5):e234-40
pubmed: 23943894
BMC Cancer. 2018 Oct 5;18(1):958
pubmed: 30290775
J Clin Oncol. 2017 Aug 10;35(23):2604-2612
pubmed: 28586243
Breast Cancer Res Treat. 2016 Sep;159(2):327-33
pubmed: 27510185
Nat Clin Pract Neurol. 2007 Jun;3(6):331-40
pubmed: 17549059
Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):125-137
pubmed: 29378785
Ann Epidemiol. 2003 Oct;13(9 Suppl):S5-17
pubmed: 14575938
Crit Rev Oncol Hematol. 2012 Apr;82(1):51-77
pubmed: 21908200
Int J Gynecol Cancer. 2007 Mar-Apr;17(2):387-93
pubmed: 17362317
Breast Care (Basel). 2019 Apr;14(2):111-116
pubmed: 31798383
N Engl J Med. 1999 Dec 30;341(27):2061-7
pubmed: 10615079
J Clin Oncol. 2012 Sep 1;30(25):3051-7
pubmed: 22851566
Cancer. 2003 Aug 15;98(4):822-31
pubmed: 12910528
Int J Gynecol Cancer. 2003 Nov-Dec;13(6):741-8
pubmed: 14675309
Oncologist. 2019 May;24(5):617-623
pubmed: 30409792
Control Clin Trials. 1998 Feb;19(1):61-109
pubmed: 9492970
Support Care Cancer. 2009 Dec;17(12):1483-91
pubmed: 19330359
Acta Oncol. 2017 Feb;56(2):190-197
pubmed: 28055266
J Natl Cancer Inst. 2014 Sep 29;106(9):
pubmed: 25265940
J Clin Oncol. 2016 Sep 1;34(25):3014-22
pubmed: 27325863
J Clin Oncol. 2012 Sep 10;30(26):3297-303
pubmed: 22649133
Eur J Cancer. 2005 May;41(8):1135-9
pubmed: 15911236
Clin Adv Hematol Oncol. 2008 Jun;6(6):455-67
pubmed: 18567992
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
J Natl Cancer Inst. 2018 Feb 1;110(2):
pubmed: 28954297
Breast Cancer Res Treat. 2011 Feb;125(3):767-74
pubmed: 21128110
Breast. 2016 Oct;29:31-8
pubmed: 27394676
Support Care Cancer. 2016 Apr;24(4):1571-81
pubmed: 26384827
N Engl J Med. 2008 Apr 17;358(16):1663-71
pubmed: 18420499
Eur J Cancer. 2015 Feb;51(3):292-300
pubmed: 25541155
Support Care Cancer. 2017 Jul;25(7):2241-2248
pubmed: 28204996
Stat Med. 2015 Dec 10;34(28):3661-79
pubmed: 26238958
Support Care Cancer. 2012 Dec;20(12):3355-64
pubmed: 22584733
J Neurol Neurosurg Psychiatry. 1979 Sep;42(9):793-803
pubmed: 501379
Breast Cancer Res Treat. 2017 Nov;166(2):519-526
pubmed: 28791499
Breast Cancer Res Treat. 2019 Dec;178(3):587-595
pubmed: 31456070
Int J Clin Oncol. 2013 Feb;18(1):132-8
pubmed: 22105895
Cancer. 2019 Sep 1;125(17):2945-2954
pubmed: 31090930